Oxford Biomedica: Edison Open House Healthcare 2022

Oxford Biomedica: Edison Open House Healthcare 2022

Oxford Biomedica — 3 videos in collection

Oxford Biomedica is a pioneer of gene and cell therapy with a leading position in lentiviral vector research and bioprocessing. It is listed on the London Stock Exchange and is a constituent of the FTSE 250 Index.

• Tell us about your LentiVector platform and how it positions the company in the market.
• What do you believe are the opportunities in the various vector sectors?
• What are the plans for the advancement of your proprietary pipeline?
• Do you see any changes to your traditional strategy of diversification?
• Are there potential cost-saving opportunities?
• Which milestones should investors focus on in the coming year?


You may also be interested in these:

Healthcare

Oxford Biomedica – executive interview

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.